A Study of the Safety and Pharmacology of MEGF0444A in Combination With Bevacizumab With or Without Paclitaxel in Patients With Locally Advanced or Metastatic Solid Tumors
This is a Phase Ib, open-label, dose-escalation study of MEGF0444A in combination with bevacizumab, and in combination with bevacizumab and paclitaxel as therapy for locally advanced or metastatic solid tumors.
Solid Cancers
DRUG: MEGF0444A|DRUG: bevacizumab|DRUG: paclitaxel
Incidence and nature of dose-limiting toxicities (DLTs), Days 1 to 28 of Cycle 1|Incidence, nature, and severity of adverse events, Until 90 days after last dose of study treatment
Pharmacokinetic parameters including total exposure, minimum and maximum serum concentration, clearance, and volume of distribution, Following administration of study drug
This is a Phase Ib, open-label, dose-escalation study of MEGF0444A in combination with bevacizumab, and in combination with bevacizumab and paclitaxel as therapy for locally advanced or metastatic solid tumors.